Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb 25;10(1):3398.
doi: 10.1038/s41598-020-60311-z.

Prostate Cancer Nodal Staging: Using Deep Learning to Predict 68Ga-PSMA-Positivity from CT Imaging Alone

Affiliations
Randomized Controlled Trial

Prostate Cancer Nodal Staging: Using Deep Learning to Predict 68Ga-PSMA-Positivity from CT Imaging Alone

A Hartenstein et al. Sci Rep. .

Abstract

Lymphatic spread determines treatment decisions in prostate cancer (PCa) patients. 68Ga-PSMA-PET/CT can be performed, although cost remains high and availability is limited. Therefore, computed tomography (CT) continues to be the most used modality for PCa staging. We assessed if convolutional neural networks (CNNs) can be trained to determine 68Ga-PSMA-PET/CT-lymph node status from CT alone. In 549 patients with 68Ga-PSMA PET/CT imaging, 2616 lymph nodes were segmented. Using PET as a reference standard, three CNNs were trained. Training sets balanced for infiltration status, lymph node location and additionally, masked images, were used for training. CNNs were evaluated using a separate test set and performance was compared to radiologists' assessments and random forest classifiers. Heatmaps maps were used to identify the performance determining image regions. The CNNs performed with an Area-Under-the-Curve of 0.95 (status balanced) and 0.86 (location balanced, masked), compared to an AUC of 0.81 of experienced radiologists. Interestingly, CNNs used anatomical surroundings to increase their performance, "learning" the infiltration probabilities of anatomical locations. In conclusion, CNNs have the potential to build a well performing CT-based biomarker for lymph node metastases in PCa, with different types of class balancing strongly affecting CNN performance.

PubMed Disclaimer

Conflict of interest statement

A.H., F.L., C.F., M.M., W.B. and M.M.R. declare no competing interest with respect to the relation to the work described. A.B. received fee as a speaker for Bayer, and Bender Gruppe, both outside of the current work. H.A. reports grants from Sirtex Medical, Bayer and GE Healthcare; lecture and/or travel fees from Sirtex Medical, GE Healthcare, Novartis, Eisai and Terumo. All outside the submitted work. B.H. declares the following competing interests: Grant money from the following companies or nonprofit organizations to the Dept of Radiology: Abbott, AbbVie, Ablative Solutions, Accovion, Achaogen Inc., Actelion Pharmaceuticals, ADIR, Aesculap, AGO, AIF Arbeitsgemeinschaft industrieller Forschungsvereinigungen, AIO: Arbeitsgemeinschaft Internistische Onkologie, Alexion Pharmaceuticals, Amgen, AO Foundation, Arena Pharmaceuticals, ARMO Biosciences, Inc., art photonics GmbG Berlin, ASR Advanced sleep research, Astellas, AstraZeneca, BARD, Bayer Healthcare, Bayer Schering Pharma, Bayer Vital, BBraun (Sponsoring a workshop), Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Berliner Krebsgesellschaft, Biotronik, Bioven, BMBF, Boehring Ingelheimer, Boston Biomedical Inc., BRACCO Group, Brainsgate, Bristol-Myers Squibb, Cascadian Therapeutics, Inc., Celgene, CELLACT Pharma, Celldex, Therapeutics, CeloNova BioSciences, Charité research organisatin GmbH, Chiltern, CLOVIS ONCOLOGY, INC., Covance, CUBIST, CureVac AG, Tübingen, Curis, Daiichi, DC Devices, Inc. USA, Delcath Systems, Dermira Inc. Deutsche Krebshilfe, Deutsche Rheuma Liga, DFG, DSM Nutritional Products AG, Dt. Stiftung für Herzforschung, Dynavax, Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Eli Lilly and Company Ltd. EORTC, Epizyme, INC., Essex Pharma, EU Programmes, Euroscreen S.A., Fibrex Medical Inc., Foxused Ultrasound Surgery Foundation, Fraunhofer Gesellschaft, Galena Biopharma, Galmed Research and Development Ltd., Ganymed, GE, Genentech Inc., GETNE (Grupo Espanol de Tumores Neuroendocrinos), Gilead Sciences, Inc, Glaxo Smith Kline, Glycotope GmbH, Berlin, Goethe Uni Frankfurt, Guerbet, Guidant Europe NV, Halozyme, Hewlett Packard GmbH, Holaira Inc. ICON (CRO), Idera Pharmaceuticals, Inc., Ignyta, Inc. Immunomedics Inc., Immunocore, Incyte, INC Research, Innate Pharma, InSightec Ltd., Inspiremd, inVentiv Health Clinical UK Ltd., Inventivhealth, IOMEDICO, IONIS, IPSEN Pharma, IQVIA, ISA Therapeutics, Isis Pharmaceuticals Inc., ITM Solucin GmbH, Jansen, Kantar Health Gmbh (CRO), Kartos Therapeutics, Inc., Karyopharm Therapeutics, Inc., Kendle/MorphoSys Ag, Kite Pharma, Kli Fo Berlin Mitte, La Roche, Land Berlin, Lilly GmbH, Lion Biotechnology, Lombard Medical, Loxo Oncology, Inc., LSK BioPartners; USA, Lundbeck GmbH, Lux Biosciences, LYSARC, MacroGenics, MagForce, MedImmune Inc., Medpace, Medpace Germany GmbH (CRO), MedPass (CRO), Medronic, Merck, Merromack Pharmaceuticals Inc., MeVis Medical Solutions AG, Millennium Pharmaceuticals Inc., Mologen, Monika Kutzner Stiftung, MSD Sharp, NeoVacs SA, Newlink Genentics Corporation, Nexus Oncology, NIH, Novartis, novocure, Nuvisan, Ockham oncology, OHIRC Kanada, Orion Corporation Orion Pharma, Parexel CRO Service, Perceptive, Pfizer GmbH, Pharma Mar, Pharmaceutical Research Associates GmbH (PRA), Pharmacyclics Inc., Philipps, PIQUR Therapeutics Ltd., Pluristem, PneumRX.Inc, Portola Pharmaceuticals, PPD (CRO), PRAint, Premier-research, Provectus Biopharmaceuticals, Inc., psi-cro, Pulmonx International Sàrl, Quintiles GmbH, Regeneron Pharmaceuticals, Inc., Respicardia, Roche, Samsung, Sanofi, sanofis-aventis S.A., Schumacher GmbH (Sponsoring a workshop), Seattle Genetics, Servier (CRO), SGS Life Science Services (CRO), Shore Human Genetic Therapies, Siemens, Silena Therapeutics, Spectranetics GmbH, Spectrum Pharmaceuticals, St. Jude Medical, Stiftung Wolfgang Schulze, Symphogen, Taiho Oncology, Inc., Taiho Pharmaceutical Co., TauRx Therapeutics Ltd., Terumo Medical Corporation, Tesaro, tetec-ag, TEVA, Theorem, Theradex, Threshold Pharmaceuticals Inc., TNS Healthcare GmbH, Toshiba, UCB Pharma, Uni München, VDI/VDE, Vertex Pharmaceuticals Incorporated, winicker-norimed, Wyeth Pharma, Xcovery Holding Company, Zukunftsfond Berlin (TSB). TP receives grant support from the Berlin Institute of Health within the Clinician Scientist Programme. TP declares no additional conflict of interest with respect to the relation to the work described. Outside of the current work there are institutional relationship with the following entities (no personal payments to TP): research support from Siemens Healthcare and Philips Healthcare, clinical trials with AGO, Aprea AB, Astellas Pharma Global Inc., AstraZeneca, Celgene, Genmab A/S, Incyte Coporation, Lion Biotechnologies, Inc., Millennium Pharmaceuticals, Inc., Morphotec Inc., MSD, Tesaro Inc., and Roche.

Figures

Figure 1
Figure 1
Generation of Labelled Dataset. (a) Imaging of a single patient with (1) a contrast-enhanced CT scan and (2) a 68Ga-PSMA PET scan. An average of 4.72 ± 0.77 lymph nodes were selected and semi-automatically segmented for each patient. A single lymph node positive for infiltration by PCa can be seen in the mediastinal region outlined in red in the CT image in (a1), and demarcated by a red arrow in PET scan in (a2). Using the 68Ga-PSMA PET/CT as our reference standard, a label for infiltration status by prostate cancer (either positive or negative) was assigned on a per lymph node basis. (b) An example of a negative 68Ga-PSMA PET/CT image pair in which the centered lymph node does not exceed background. (c) An example of a positive image pair.
Figure 2
Figure 2
Dataset Generation Flowchart. Diagram describing generation of train and test datasets. Three train datasets shown, (status balanced, location balanced and xMask) were used to train three distinct neural networks. All neural networks and experts were tested and compared using a separate test set of 130 images, which was withheld from the neural networks during training. 50:50 class balancing was performed by taking all available infiltrated lymph nodes and randomly selecting an equally sized set of non-infiltrated lymph nodes, either from all available non-infiltrated nodes or from nodes within the same location category.
Figure 3
Figure 3
Dataset Regional and Volume Distributions. (a) The final distribution of lymph node images by location and infiltration status for the two training sets, referred to as ‘status balanced’ with 732 images and ‘location balanced’ with 548 images. (b) Boxplots depicting volume distribution for the location and status balanced training sets and test set grouped by infiltration status. Due to considerable overlap of the two distributions, size or volume is not a powerful indicator of infiltration.
Figure 4
Figure 4
Convolutional neural network architecture. All three CNNs developed shared a common architecture and differed by the data used for training. CNNs received 2D contrast-enhanced CT images and segmentation masks as input, with input images augmented randomly during training. All convolutional layers used a kernel size of 3 × 3. A rectified linear unit (ReLU) activation function followed by batch normalization was performed at every layer. Adam optimization was used to update network weights, with parameters for alpha, beta1, beta2 and epsilon set at 0.0001, 0.9, 0.999 and 1e-08. Training was continued for 50 epochs.
Figure 5
Figure 5
Classification performance. (a) Shown are the ROC curves for the three trained CNNs on the separate test set (n = 130) with 95% confidence interval of the sensitivity at given specificities in shaded gray. Displayed in the lower right hand corner is the corresponding AUC. Classification by individual radiologists on the same test set are displayed as black dots. Blue stars show random forest performance on the separate test set using the corresponding training dataset (status or location balanced). (b) Histograms of CNN model classification performance on the test set. The threshold that maximizes Youden’s index is shown as a dashed line. The threshold which corresponds to a 90% sensitivity is shown as a dotted line. Infiltrated nodes (red bars) to the right of the given threshold are ‘true positive’, while those to the left are ‘false negative’: non-infiltrated nodes (blue) to the left are true negative, to the right are false positive.
Figure 6
Figure 6
Heatmaps display neural network attention. (a) Contrast-enhanced CT images for two lymph nodes that were used as input to generate all heatmaps displayed, with (1) a retroperitoneal lymph node positive for infiltration by PCa, and (2) an inguinal lymph node negative for infiltration. In (b–d) heatmaps for the lymph nodes shown in (a), produced by three CNNs trained with status balanced training data, location balanced training data, or masked input data, respectively. CNN output, a pseudo probability score that the lymph node was classified as positive for tumor infiltration, is shown in the bottom right of each heatmap in (b–d). Stars signify true output predictions (either true positives for the lymph node in column 1 or true negative for column (2), with thresholds set by optimizing Youden’s index for each CNN, set at 34, 73 and 54 for b,c, and d respectively. Within heatmaps, light colors represent areas that contribute to output prediction, while dark regions contribute little to output prediction. CNNs often highlight regions within the lymph node that expert radiologists recognize as important for infiltration status, such as nodal center density and contrast enhancement. In true positive images it appears that high central density is the most relevant parameter in designating a ‘positive’ label. We postulate that the ‘halo’ surrounding the lymph node in the xMask CNN (d1), depicts the CNN attention to size. Heatmaps produced by the CNN trained with status balanced data highlight anatomical regions which aid in classification of lymph nodes, often demarcating the air-skin border seen in images of inguinal lymph nodes, as in b2.
Figure 7
Figure 7
Limitations of heatmaps as tool to explain black box predictions. (a) Contrast-enhanced CT images for two inguinal lymph nodes that were used as input to generate all heatmaps displayed, with (1) a lymph node positive for infiltration by PCa, and (2) a lymph node negative for infiltration. In (b,c) heatmaps produced by two CNNs trained with location balanced training data, or masked input data, respectively. Beyond verifying that the lymph node is important for classification, heatmaps provide little additional information as to why classification output was either true positive (b1,c1), true negative (b2), or false positive (c2).

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Oderda M, Joniau S, Spahn M, Gontero P. Debulking surgery in the setting of very high-risk prostate cancer scenarios. BJU Int. 2012;110:E192–E198. doi: 10.1111/j.1464-410X.2012.10942.x. - DOI - PubMed
    1. Luchini C, et al. Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. Sci. Rep. 2017;7:2374. doi: 10.1038/s41598-017-02577-4. - DOI - PMC - PubMed
    1. Carroll PR, et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J. Natl Compr. Canc Netw. 2016;14:509–519. doi: 10.6004/jnccn.2016.0060. - DOI - PMC - PubMed
    1. Mottet N, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2017;71:618–629. doi: 10.1016/j.eururo.2016.08.003. - DOI - PubMed

Publication types